A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Eligibility Criteria

• * Provide electronic or written informed consent, either personally or through a legally authorized representative
• * Age ≥18 years
• * Current hospitalization or recently discharged with the primary diagnosis of heart failure
• * Heart failure signs and symptoms at the time of hospital admission
• * Imaging evidence of mildly reduced or preserved left ventricular ejection fraction (EF) (40% or higher)
• * Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥1000 pg/mL or B-type natriuretic peptide (BNP) ≥250 pg/mL for patients without atrial fibrillation (AF); or elevated NTproBNP ≥2000 pg/mL or BNP ≥500 pg/mL for patients with AF
• * Treatment with a mineralocorticoid receptor antagonist (MRA)
• * Documented prior history of severe hyperkalemia in the setting of MRA use
• * Estimated glomerular filtration rate (eGFR) \<25 mL/min/1.73m² or serum/plasma potassium \>5.0 mmol/L at screening
• * Acute myocardial infarction, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days
• * Hemodynamically significant (severe) uncorrected primary cardiac valvular disease
• * Cardiomyopathy due to known acute inflammatory heart, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or known pericardial constriction
• * Probable alternative cause of participant's heart failure symptoms
• * Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers